HSBC Issues Positive Forecast for Bristol Myers Squibb (NYSE:BMY) Stock Price

Bristol Myers Squibb (NYSE:BMY) had its price objective raised by equities research analysts at HSBC from $53.00 to $60.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. HSBC’s price target points to a potential downside of 0.85% from the stock’s current price.

Several other brokerages have also recently issued reports on BMY. Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Monday, November 24th. Scotiabank restated a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. UBS Group reissued a “buy” rating and set a $70.00 price target on shares of Bristol Myers Squibb in a report on Friday, March 6th. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Finally, Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their price target for the company from $52.00 to $61.00 in a research note on Monday, December 15th. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus target price of $61.41.

Bristol Myers Squibb Trading Up 1.3%

Shares of BMY stock traded up $0.81 during trading on Tuesday, hitting $60.52. 4,056,448 shares of the stock traded hands, compared to its average volume of 12,734,189. Bristol Myers Squibb has a 52-week low of $42.52 and a 52-week high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The firm has a market capitalization of $123.24 billion, a P/E ratio of 17.56, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The firm’s fifty day moving average price is $58.37 and its 200-day moving average price is $51.55.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter in the prior year, the firm posted $1.67 EPS. Bristol Myers Squibb’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts forecast that Bristol Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Osbon Capital Management LLC acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth about $55,000. World Investment Advisors grew its stake in Bristol Myers Squibb by 14.1% in the 4th quarter. World Investment Advisors now owns 64,471 shares of the biopharmaceutical company’s stock worth $3,478,000 after acquiring an additional 7,977 shares during the period. Nalls Sherbakoff Group LLC purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at $92,000. Larry Mathis Financial Planning LLC purchased a new stake in Bristol Myers Squibb in the 4th quarter valued at about $427,000. Finally, Corient Private Wealth LLC grew its holdings in Bristol Myers Squibb by 7.5% in the fourth quarter. Corient Private Wealth LLC now owns 489,348 shares of the biopharmaceutical company’s stock valued at $26,418,000 after purchasing an additional 33,958 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.